

DAFTAR PUSTAKA

1. Pangribo S. Pusat Data dan Informasi Kementerian Kesehatan RI : Beban Kanker di Indonesia. Riskesdas. Jakarta Selatan: Kementerian Kesehatan Republik Indonesia; 2019. 1–16 p.
2. Organization WH. Cancer [Internet]. www.who.int. 2018 [cited 2022 Mar 8]. Available from: <https://www.who.int/health-topics/cancer>
3. Kementerian Kesehatan Republik Indonesia. Hasil Utama RISKESDAS 2018 Kesehatan (Main Result of Basic Health Research) [Internet]. Riset Kesehatan Dasar (Riskesdas). 2018 [cited 2022 Mar 3]. p. 1–128. Available from: <https://www.litbang.kemkes.go.id/hasil-utama-riskesdas-2018/>
4. Bruce S SJ. Gestational Trophoblastic Disease [Internet]. Pubmed; 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470267/>
5. Silva ALM da, Monteiro K do N, Sun SY, Borbely AU. Gestational trophoblastic neoplasia: Novelties and challenges. *Placenta*. 2021;116(1):1–5.
6. AlJulaih GH MM. Gestational Trophoblastic Neoplasia [Internet]. Pubmed; 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562225/>
7. Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Update on the diagnosis and management of gestational trophoblastic disease. *Int J Gynecol Obstet*. 2018;143(2):79–85.
8. Ayu Mei Wulandari. Literature review perubahan ekspresi bcl-2 pada koriokarsinoma. *Fak Kedokt Univeristas Brawijaya*. 2020;(1):60.
9. Soper JT. Gestational Trophoblastic Disease Current Evaluation and Management. *Obstet Gynecol by Wolters Kluwer Heal*. 2021;137(2):355–70.
10. Whiting F. The placenta: What it is and how it works. baby Cent [Internet]. 2021; Available from: <https://www.babycentre.co.uk/a25036426/the-placenta-what-it-is-and-how-it-works>
11. F. Gary Cunningham M. *Obstetri Williams Edisi 23*. 23rd ed. Jakarta: Buku Kedokteran EGC; 2013. 1326 p.
12. Prawiroharjo S. *Ilmu Kebidanan*. 4th ed. Jakarta: PT. Bina Pustaka Sarwono Prawirohardjo; 2016. 981 p.
13. Azizi AR, Mahendra INB, Widiyanti ES. Profil Pasien Penyakit Trofoblastik Gestasional di RSUP Sanglah Denpasar periode 1 Januari 2017 Sampai 31 Desember 2017. *J Med Udayana* [Internet]. 2019;8(7):1–10. Available from: <https://ojs.unud.ac.id/index.php/eum>
14. Amelia V, Sari RDP. Penyakit Trofoblastik Gestasional: Varian Histopatologi Mola Hidatidosa. *Med Prof J Lampung*. 2020;10(3):514–9.

15. Demir H, Duran N. Sağlık Bilimlerinde Güncel Araştırmalar. Turkey: Stamparija Ivpe; 2020. 757 p.
16. Andi Friadi. Update on the Diagnosis of Gestational Trophoblastic Disease. UMI Med J [Internet]. 2019;4(1):117–29. Available from: <http://jurnal.fk.umi.ac.id/index.php/umimedicaljournal%0AUpdate>
17. Reksohusodo S, Nurseta T. Produksi Total Reactive Oxygen Species pada Kultur Jaringan Mola Hydatidosa Komplit dengan Pemaparan 17-Beta Estradiol. Maj Kesehat Fak Kedokt Univ Brawijaya. 2021;8(2):64–9.
18. Soeharyono, Sanusi I, Hakimi M. Faktor-faktor risiko Penyakit Trofoblas. Bagian Ilmu Kebidanan dan Penyakit Kandung Fak Kedokt Univ Gajah Mada. 1996;28(2):83–90.
19. dr. Ratna Dewi Puspita Sari, S.Ked SO, dr. Arif Yudho Prabowo SK. Buku Ajar Kehamilan Perdarahan pada Kehamilan Trimester 1. Bandar Lampung: LPPM UNILA IR; 2019. 67 p.
20. Dewi R. Gambaran Kejadian Mola Hidatidosa Di Rumah Sakit Abdul Moeloek Provinsi Lampung. J Kesehat Panca Bhakti Lampung. 2018;6(1):30–4.
21. Octiara DL, Sari RDP. Mola Hidatidosa. J Kedokt Univ Lampung. 2021;5(1):50–3.
22. Andriana R, Islamy N. Kehamilan mola hidatidosa disertai hipertiroid. JIMKI J Ilm Mhs Kedokt Indones. 2020;8(2):3–9.
23. Purba YS, Munir MA, Saranga D. Mola hidatidosa. J Med Prof. 2019;1(1):79–86.
24. Utami N. Karakteristik pasien dengan mola hidatidosa di Rumah Sakit Muhammadiyah Palembang dari Januari 2018 sampai Desember 2020. Fak Kedokt Univ Muhammadiyah Palembang. 2021;(1):47.
25. Harahap IL, Ni Wajan Tirthaningsih. Mola Hidatidosa. Maj Biomorfologi. 2014;27(1):14–20.
26. Ning F, Hou H, Morse AN, Lash GE. Understanding and management of gestational trophoblastic disease [version 1; peer review: 2 approved]. F1000Research. 2019;428(1):8.
27. Berkowitz RS, Goldstein DP. Molar pregnancy. N Engl J Med. 2009;(1):67–74.
28. Wang K, Chen Y. Management and prognostic analysis of patients with gestational trophoblastic neoplasia (GTN) in FIGO stage IV and its special type. Clin Exp Metastasis [Internet]. 2021;38(1):47–59. Available from: <https://doi.org/10.1007/s10585-020-10064-w>

29. Mousavi AS, Zamani A, Khorasanizadeh F, Gilani MM, Zendehtdel K. Resistance to single-agent chemotherapy and its risk factors in low-risk gestational trophoblastic neoplasms. *J Obstet Gynaecol Res*. 2015;41(5):776–83.
30. Balachandran K, Salawu A, Ghorani E, Kaur B, Sebire NJ, Short D, et al. When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients. *Gynecol Oncol* [Internet]. 2019;155(1):8–12. Available from: <https://doi.org/10.1016/j.ygyno.2019.07.024>
31. Wargasetia TL, Nataprawira HMD, Shahib MN. Aspek Patobiologis pada Penyakit Trofoblas Gestasional. *Maranatha J Med Heal*. 2011;2(2):190–205.
32. Horowitz NS, Eskander RN, Adelman MR, Burke W. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation. *Gynecol Oncol* [Internet]. 2021;163(3):605–13. Available from: <https://doi.org/10.1016/j.ygyno.2021.10.003>
33. Jackson Sinaga R, D. L. Tobing M, Budi Harsono A. Karakteristik Pasien Tumor Trofoblas Gestasional Risiko Rendah dengan Kemoresistensi terhadap Metotreksat yang Dirawat di RSUP Dr. Hasan Sadikin Bandung Periode 2011–2015. *Indones J Obstet Gynecol Sci*. 2018;1(2):147–54.
34. Prawirohardjo S. Ilmu Kandungan. 3rd ed. Jakarta: PT. Bina Pustaka Sarwono Prawirohardjo; 2017. 604 p.
35. Coletta JM, Hou JY, D’Alton ME. *Obstetric Imaging: Fetal Diagnosis and Care*. 2nd ed. Elsevier; 2017. 439-440.e1 p.
36. Jaremit N, Horowitz NS, Goldstein DP, Berkowitz RS, Elias KM. EMA vs EMACO in the treatment of gestational trophoblastic neoplasia. *Gynecol Oncol* [Internet]. 2020;158(1):99–104. Available from: <https://doi.org/10.1016/j.ygyno.2020.04.699>
37. Aminimoghaddam S, Nezhadisalami F, Anjidani S, Tond SB. Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/etoposide and cisplatin) regimen in gestational trophoblastic neoplasia. *Med J Islam Repub Iran*. 2018;32(1):210–3.
38. Katzung BG. *Farmakologi dasar & Klinik*. 12th ed. Jakarta: Buku Kedokteran EGC; 2017. 652 p.
39. Hardman JG. *Goodman & Gilman Dasar Farmakologi Terapi*. 10th ed. Jakarta: Buku Kedokteran EGC; 2012. 624 p.
40. Gunawan SG. *Farmakologi dan Terapi*. 6th ed. Jakarta: Badan Penerbit FK UI; 2016. 932 p.

41. Rajuddin, Rini RF, Nurjannah. Hubungan kadar progesteron dan β -HCG dengan abortus pada kehamilan \leq 12 minggu di Klinik Rasi Banda Aceh. *Kedokt Dan Kesehat Malikussaleh*. 2016;2(1):21–9.
42. Betz D FK. Human Chorionic Gonadotropin [Internet]. Pubmed; 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK532950/>
43. Sherwood L. Fisiologi Manusia dari Sel ke Sistem [Internet]. 9th ed. Jakarta: Penerbit Buku Kedokteran EGC; 2018. 896–897 p. Available from: <http://114.7.97.203:8123/inlislite3/opac/detail-opac?id=13020>
44. Harti AS, Estuningsih, Nurkusumawati H. Pemeriksaan HCG (human chorionic gonadotropin) untuk deteksi kehamilan dini secara immunokromatografi. *J KesMaDaSka*. 2013;1(1):1–4.
45. Debra Rose Wilson, Ph.D., MSN, R.N., IBCLC, AHN-BC C. HCG levels in pregnancy. *Med News Today* [Internet]. 2020; Available from: <https://www.medicalnewstoday.com/articles/hcg-levels>
46. Zulhij DI, Parewasi H, Sabir M. Wanita 21 tahun dengan mola hidatidosa: laporan kasus. *J Med Prof*. 2020;2(2):118–23.
47. Dewi YR. Hubungan antara usia ibu hamil dengan kejadian mola hidatidosa kompli di RSUD Jombang periode januari 2009-Desember 2010. *Fak Kedokt Univ Muhammadiyah Malang*. 2011;(1):4–36.
48. Sastroasmoro S, Ismael S. *Dasar-dasar Metodologi Penelitian Klinis*. 5th ed. Jakarta: Sagung Seto; 2016. 522 p.
49. Sirimusika N, Boonyapipat S. Serum human chorionic gonadotropin ratios for the detection of etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance in high-risk gestational trophoblastic neoplasia. *Heal Sci Reports by Wiley Period LLC*. 2022;5(4):1–7.
50. Essel KG, Bruëgl A, Gershenson DM, Ramondetta LM, Naumann RW, Brown J. Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility? *Gynecol Oncol* [Internet]. 2017;146(1):1–7. Available from: <http://dx.doi.org/10.1016/j.ygyno.2017.04.017>
51. Braga A, Elias KM, Horowitz NS, Berkowitz RS. Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. *Best Pract Res Clin Obstet Gynaecol* [Internet]. 2021;74(1):1–16. Available from: <https://doi.org/10.1016/j.bpobgyn.2021.01.005>
52. Li J, Yue H, Wang X, Chen R, Lu X. Chemotherapy for gestational trophoblastic neoplasia patients with a FIGO score of 12 or greater: A multistudy analysis. *Eur J Obstet Gynecol Reprod Biol* [Internet]. 2019;238(419):164–9. Available from: <https://doi.org/10.1016/j.ejogrb.2019.05.023>

53. Angelina YA, Hartono P. Characteristics of gestational thropoblast tumor in Dr. Soetomo Hospital, year 2015-2017. *Maj Obstet Ginekol*. 2019;27(2):79.
54. Gupta S, Jhirwal M, Sharma C, Shekhar S. A Rare Case of Gestational Choriocarcinoma with Lung and Vaginal Metastases with Obstructive Jaundice. *J Obstet Gynecol India* [Internet]. 2022;72(3):262–4. Available from: <https://doi.org/10.1007/s13224-021-01490-1>
55. Sharami SRYS, Saffarieh E. A review on management of gestational trophoblastic neoplasia. *J Fam Med Prim Care* [Internet]. 2020;9(3):1287–95. Available from: www.jfmprc.com
56. Descargues P, Hajri T, Massardier J, Lotz JP, Devouassoux-Shisheboran M, Allias Montmayeur F, et al. Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France. *Am J Obstet Gynecol*. 2021;225(4):401.e1-401.e9.
57. Kaur B. Pathology of gestational trophoblastic disease (GTD). *Best Pract Res Clin Obstet Gynaecol* [Internet]. 2021;74(1):3–28. Available from: <https://doi.org/10.1016/j.bpobgyn.2021.02.005>
58. Kong Y, Tao G, Zong L, Yang J, Wan X, Wang W, et al. Diagnosis and Management of Mixed Gestational Trophoblastic Neoplasia: A Study of 16 Cases and a Review of the Literature. *Front Oncol*. 2019;9(1):1–8.
59. Noer Islami IP, Suardi D, Husni Syam H, Ritonga M. Faktor Risiko Kejadian Tumor Trofoblas Gestasional Pasca Evakuasi Molahidatidosa di RSUP Dr. Hasan Sadikin Bandung Periode Agustus 2013–Agustus 2018. *Indones J Obstet Gynecol Sci*. 2020;3(2):106–12.
60. Freitas F, Braga A, Viggiano M, Velarde LGC, Maesta I, Uberti E, et al. Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. *Gynecol Oncol* [Internet]. 2020;158(2):452–9. Available from: <https://doi.org/10.1016/j.ygyno.2020.04.704>
61. Winata IGS, Aricandana PAE. Systematic Review Kemoterapi EMA dan EMACO dalam Risiko Tinggi Penyakit Trofoblas Gestasional, Mana yang Lebih Baik? *Indones J Obstet Gynecol*. 2022;10(3):184–7.
62. Bonggao BJA, Soriano-Estrella AL. Comparison of the clinical response of high-risk and ultra high-risk gestational trophoblastic neoplasia to etoposide-methotrexate-actinomycin-cyclophosphamide-vincristine: Experience at the Philippine General Hospital. *Philipp J Obstet Gynecol*. 2020;44(4):12–8.